EGFR and colorectal carcinoma: As all known, the status of KRAS gene is closely related to the prognosis of CRC patients and their response to treatments including anti-EGFR treatment, ICI therapy, and even chemotherapy; therefore, more about KRAS mutation should be put into account for therapy choice and management of CRC patients.